Literature DB >> 18201934

Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules.

Franklin Johnson1, George Wagner, Stephen Sun, Joseph Stauffer.   

Abstract

UNLABELLED: The recent withdrawal of hydromorphone hydrochloride extended-release capsules (Palladone; Purdue Pharma L.P., Stamford, CT) from the market after pharmacokinetic data revealed a risk of alcohol-induced dose-dumping prompted a re-examination of the risk-benefit profiles of extended-release drugs. Although warnings on concomitant alcohol use are included on opioid product labels, further investigations of extended-release formulations to determine the risk of dose-dumping were recommended by the US Food and Drug Administration. The present study was undertaken to assess the single-dose relative bioavailability of polymer-coated, extended-release morphine sulfate capsules (KADIAN, 100 mg; Alpharma Pharmaceuticals LLC, Piscataway, NJ). This open-label, randomized, 3-way crossover study with an additional index arm, conducted among 32 healthy male volunteers, found no significant evidence of a formulation interaction between KADIAN and alcohol, in vivo. The pharmacokinetics of serum morphine did not differ significantly among subjects taking KADIAN with water (fasted) or with 240 mL 40% alcohol under fasted or fed conditions. Analysis of variance ratios of least-squares means for ln-transformed AUC(infinity) and C(max) satisfied the criteria (90% confidence intervals within 80%-125%) to declare no drug formulation interaction among the KADIAN regimens dosed with alcohol compared with KADIAN taken with water. There were no serious adverse events or deaths reported during the study. PERSPECTIVE: Because of the high rate of alcohol use in the United States, the potential for drug-alcohol interactions is an important clinical concern. Although it is recommended that alcohol not be used while the patient is taking opioids, results of this in vivo study indicate that the risk of alcohol-induced dose-dumping in connection with the use of KADIAN is negligible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201934     DOI: 10.1016/j.jpain.2007.11.009

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  7 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

2.  Development and Optimization of a Novel Prolonged Release Formulation to Resist Alcohol-Induced Dose Dumping.

Authors:  Chaitanya Yogananda Gujjar; Balaramesha Chary Rallabandi; Ramesh Gannu; Vallabh Subashrao Deulkar
Journal:  AAPS PharmSciTech       Date:  2015-07-11       Impact factor: 3.246

Review 3.  Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review.

Authors:  Simeon Kimmel; Paxton Bach; Alexander Y Walley
Journal:  J Gen Intern Med       Date:  2020-05-27       Impact factor: 5.128

4.  Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers.

Authors:  Stephen J Farr; Cynthia Y Robinson; Christopher M Rubino
Journal:  Clin Pharmacol       Date:  2015-01-19

5.  Update on prescription extended-release opioids and appropriate patient selection.

Authors:  Michael J Brennan
Journal:  J Multidiscip Healthc       Date:  2013-07-23

6.  Approach to the pharmacological management of chronic pain in patients with an alcohol use disorder.

Authors:  Laura Murphy; Karen Wk Ng; Victoria Ch Su; Sarah Woodworth-Giroux; Todd S Levy; Beth A Sproule; Andrea D Furlan
Journal:  J Pain Res       Date:  2015-11-30       Impact factor: 3.133

7.  Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol(®) 888ATO as Lipid Excipient.

Authors:  Shilpa N Patere; Chhanda J Kapadia; Mangal S Nagarsenker
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.